Deadline Approaching: Boston Scientific Corporation (BSX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
MWN-AI** Summary
The Law Offices of Howard G. Smith has issued a reminder to Boston Scientific Corporation (BSX) shareholders who experienced financial losses during the Class Period, from July 23, 2025, to February 3, 2026. Investors are urged to file a lead plaintiff motion by the approaching deadline of May 4, 2026, as part of a securities fraud class action lawsuit against the company.
The lawsuit stems from a significant drop in Boston Scientific's stock price following its fourth-quarter earnings report on February 4, 2026. The report revealed disappointing results in its U.S. Electrophysiology (EP) sales, alongside fiscal guidance for 2026 that fell short of expectations. Boston Scientific attributed these disappointing outcomes to slower-than-anticipated market growth and intensified competition—contradicting earlier assurances regarding the growth prospects of the EP business and anticipated market dynamics. Following this news, Boston Scientific shares plummeted by $16.12, or 17.6%, closing at $75.50 per share.
The complaint alleges that the company and its officials made materially false and misleading statements, failing to disclose critical facts detrimental to the company’s operations and prospects. Key accusations include misleading representations about the sustainability of growth rates in the U.S. EP segment and the impact of emerging competition on market share.
Investors who bought or acquired Boston Scientific securities during this period may be eligible for participation in this lawsuit. Those interested in learning more about their rights or wishing to get involved should contact the Law Offices of Howard G. Smith via email or phone provided in the announcement.
MWN-AI** Analysis
Investors in Boston Scientific Corporation (NYSE: BSX) are facing significant challenges following disappointing financial results and a subsequent sharp decline in stock price. As shareholders grapple with losses stemming from the Class Period, which runs from July 23, 2025, to February 3, 2026, they are encouraged to consider participation in a potential class action lawsuit.
The catalyst for this legal action was a disappointing earnings report released on February 4, 2026, which revealed underwhelming performance in the U.S. Electrophysiology (EP) market and provided fiscal guidance for 2026 that fell short of market expectations. The reported decline in sales raised concerns about the viability of Boston Scientific’s growth strategy, particularly as the company had previously projected robust growth despite signs of increasing competition. The stock plummeted by 17.6%, a steep decline that highlights the market’s reaction to a perceived credibility gap between management’s statements and the reality facing the company.
In light of these events, shareholders who bought into Boston Scientific during the affected period might consider joining the class action as a way to seek recovery for their losses. Taking action before the May 4, 2026, deadline is crucial for those eligible. Engaging legal counsel familiar with securities litigation could provide valuable insights into the process and potential outcomes.
Market participants should also keep a close eye on future developments from Boston Scientific, including any updates on its competitive positioning and strategic adjustments in response to challenges identified in the lawsuit. As the case develops, understanding the implications on the company’s overall market strategy may shed light on its long-term viability and potential for recovery.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Law Offices of Howard G. Smith reminds investors of the upcoming May 4, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX ) securities between July 23, 2025 and February 3, 2026 , inclusive (the “Class Period”).
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BOSTON SCIENTIFIC CORPORATION (BSX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com , by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com .
What Happened?
On February 4, 2026, Boston Scientific reported fourth quarter and full year 2025 results, including a disappointment in U.S. Electrophysiology sales, and issued fiscal 2026 guidance — including for the first half of 2026 — that fell below expectations. The Company attributed the results to slower than expected market growth and increased competition, despite prior statements describing the EP business as “growing” and asserting it had “a very good understanding of what competition we will face and in what time frame.”
On this news, Boston Scientific’s stock price fell $16.12, or 17.6%, to close at $75.50 per share on February 4, 2026, thereby injuring investors.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Boston Scientific's U.S. EP segment's growth rate was unsustainable and was approaching an earlier tipping point than the market was anticipating; (2) the Company was experiencing new competition entrants that were sapping Boston Scientific's U.S. Electrophysiology market share and thus limiting the Company's growth potential; (3) as a result, Defendants' repeated statements of confidence in the U.S. EP division's growth trajectory, including repeatedly elevated full-year guidance metrics, were materially misleading; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
If you purchased or otherwise acquired Boston Scientific securities during the Class Period, you may move the Court no later than May 4, 2026 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements.
Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com .
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260311313885/en/
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
FAQ**
What specific events led to Boston Scientific Corporation BSX's stock price decline of 17.6% on February 4, 2026, and how might these events impact future investor confidence?
How does the ongoing securities fraud lawsuit against Boston Scientific Corporation BSX affect the company's reputation and potential recovery in the stock market?
What are the potential legal implications for investors who purchased Boston Scientific Corporation BSX securities during the Class Period and are considering joining the lawsuit?
What evidence or information do the plaintiffs in the Boston Scientific Corporation BSX case have to support their claims of misleading statements by the company's executives?
**MWN-AI FAQ is based on asking OpenAI questions about Boston Scientific Corporation (NYSE: BSX).
NASDAQ: BSX
BSX Trading
1.17% G/L:
$68.91 Last:
4,036,147 Volume:
$68.96 Open:
